GnRH Associated Peptide (GAP) (1-13), Human Mechanisms, Clin

GnRH Associated Peptide (GAP) (1-13), Human: Mechanisms, Clinical Value, and Research Perspectives

Introduction
Gonadotropin-releasing hormone (GnRH) is a decapeptide neurohormone pivotal in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, orchestrating reproductive function through the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. The GnRH precursor, prepro-GnRH, undergoes proteolytic processing to yield not only GnRH itself but also a C-terminal peptide known as the GnRH Associated Peptide (GAP). Specifically, GAP (1-13), human, corresponds to the N-terminal 13 amino acids of the full GAP sequence. While the physiological role of GnRH has been extensively characterized, the biological significance of GAP (1-13) is an emerging area of research, with evidence suggesting neuromodulatory, anti-proliferative, and immunoregulatory functions (Seong et al., 2012, Endocrinology).

Mechanistically, GAP (1-13) is believed to exert its effects through interactions with specific membrane receptors distinct from the classical GnRH receptor, modulating intracellular signaling cascades such as cAMP and calcium flux (Kim et al., 2013, J Neuroendocrinol). This peptide has been implicated in the regulation of neuronal excitability, modulation of pituitary cell function, and potential anti-tumor activity. The availability of synthetic human GAP (1-13) enables detailed in vitro and in vivo investigations, facilitating the elucidation of its pharmacological profile and therapeutic potential.

[Related: mog 35-55] Clinical Value and Applications
The clinical value of GAP (1-13), human, is rooted in its multifaceted biological activities that extend beyond the reproductive axis. Preclinical studies have highlighted its potential in several domains:

1. **Neuroprotection and Neuromodulation:** GAP (1-13) has demonstrated neuroprotective effects in models of neuronal injury, possibly by modulating glutamate-induced excitotoxicity and promoting neuronal survival (Park et al., 2015, Neuroscience Letters).

2. **Pituitary Regulation:** The peptide modulates pituitary cell proliferation and hormone secretion, suggesting a role in the fine-tuning of endocrine feedback loops (Seong et al., 2012).

3. **Anti-tumor Activity:** There is growing evidence that GAP (1-13) exerts anti-proliferative effects on certain tumor cell lines, including pituitary adenomas and gliomas, potentially via induction of apoptosis and inhibition of cell cycle progression (Lee et al., 2016, Cancer Letters).

4. **Immunomodulation:** Preliminary data indicate that GAP (1-13) may influence immune cell function, including the modulation of cytokine release and T-cell activity (Kim et al., 2013).

[Related: navitoclax price] These findings position GAP (1-13) as a promising research tool for the investigation of neuroendocrine, oncological, and immunological disorders, with the potential for future therapeutic translation.

Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting the HPG axis, such as GnRH agonists and antagonists, are associated with several limitations, including desensitization, adverse metabolic effects, and incomplete suppression of hormone-dependent pathologies (Conn & Crowley, 1994, Endocrine Reviews). GAP (1-13) addresses several key challenges:

[Related: bortezemib] - **Selective Modulation:** Unlike GnRH analogs that broadly suppress gonadotropin release, GAP (1-13) may offer more selective modulation of pituitary and neuronal functions, potentially reducing systemic side effects.

- **Neuroprotection:** There is a paucity of neuroprotective agents that can be safely administered in the context of neuroendocrine disorders. GAP (1-13) provides a novel avenue for neuroprotection without disrupting reproductive hormone balance.

- **Anti-tumor Potential:** Hormone-dependent tumors often develop resistance to conventional therapies. GAP (1-13) may circumvent this by targeting alternative signaling pathways involved in tumor growth and survival.

- **Immunomodulation:** The dual neuroendocrine and immunomodulatory actions of GAP (1-13) address the need for agents that can modulate immune responses in the context of neuroinflammatory and autoimmune diseases.

Literature Review
A growing body of literature supports the diverse biological activities of GAP (1-13), human:

1. **Seong et al. (2012, Endocrinology):** This seminal study demonstrated that GAP (1-13) modulates pituitary cell proliferation and hormone secretion via cAMP-dependent pathways, independent of the classical GnRH receptor.

2. **Kim et al. (2013, Journal of Neuroendocrinology):** The authors reported that GAP (1-13) influences neuronal excitability and synaptic plasticity in hippocampal neurons, suggesting a neuromodulatory role.

3. **Park et al. (2015, Neuroscience Letters):** In a model of glutamate-induced neurotoxicity, GAP (1-13) treatment reduced neuronal cell death and attenuated oxidative stress markers.

4. **Lee et al. (2016, Cancer Letters):** This study provided evidence for the anti-proliferative effects of GAP (1-13) on pituitary adenoma and glioma cell lines, mediated by caspase-dependent apoptosis.

5. **Conn & Crowley (1994, Endocrine Reviews):** While not directly focused on GAP, this review contextualizes the limitations of current GnRH-based therapies and underscores the need for novel modulators of the HPG axis.

6. **Kakar et al. (2018, Molecular and Cellular Endocrinology):** The authors discuss the processing of prepro-GnRH and the emerging roles of GAP peptides in neuroendocrine regulation.

7. **Miyamoto et al. (2020, Frontiers in Endocrinology):** This review highlights the broader spectrum of GnRH-associated peptides in vertebrate physiology and their potential as therapeutic targets.

Collectively, these studies underscore the unique and versatile actions of GAP (1-13), supporting its continued investigation as a research tool and potential therapeutic agent.

Experimental Data and Results
Experimental investigations into GAP (1-13), human, have employed a variety of in vitro and in vivo models to elucidate its biological effects:

- **Pituitary Cell Proliferation:** Seong et al. (2012) utilized primary rat pituitary cell cultures treated with synthetic GAP (1-13). The peptide significantly inhibited cell proliferation (p < 0.01) and reduced LH secretion by 30% compared to controls, effects reversed by a cAMP pathway inhibitor.

- **Neuroprotection:** Park et al. (2015) exposed cultured hippocampal neurons to glutamate in the presence or absence of GAP (1-13). Neuronal viability increased by 25% (p < 0.05) in the GAP-treated group, with concomitant reductions in reactive oxygen species and caspase-3 activation.

- **Anti-tumor Activity:** Lee et al. (2016) treated human pituitary adenoma and glioma cell lines with varying concentrations of GAP (1-13). Dose-dependent decreases in cell viability were observed, with IC50 values of 12 μM and 18 μM, respectively. Flow cytometry confirmed increased apoptotic cell populations.

- **Immunomodulation:** Kim et al. (2013) reported that GAP (1-13) modulates cytokine release in activated T-cells, reducing IL-2 and IFN-γ secretion by 20-30% in vitro.

These experimental results corroborate the multifunctional profile of GAP (1-13), supporting its utility in neuroendocrine, oncological, and immunological research.

Usage Guidelines and Best Practices
The application of synthetic GAP (1-13), human, in research settings requires careful consideration of peptide handling, dosing, and experimental design:

- **Reconstitution:** GAP (1-13) is typically supplied as a lyophilized powder. It should be reconstituted in sterile water or appropriate buffer (e.g., PBS) to the desired concentration, with aliquots stored at -20°C to -80°C to prevent degradation.

- **Concentration Range:** In vitro studies commonly employ concentrations ranging from 1 μM to 50 μM, depending on cell type and experimental endpoint. Dose-response assessments are recommended to determine optimal concentrations for specific applications.

- **Administration:** For in vivo studies, GAP (1-13) can be administered via intracerebroventricular, intraperitoneal, or subcutaneous routes. Dosage regimens should be guided by prior pharmacokinetic and toxicity data, with initial Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 39 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559059